Although these proteins are not surface markers and are therefore difficult for analysis, they helped to define two separate MDSC groups, CD33+ HLA-DR−/low STAT3+ and CD11b+ HLA-DR−/low c/EBPβ+, which provided novel diagnostic and therapeutic tools for cancer immunotherapy [105]. The gene discussed is STAT3; the disease is cancer.